AD/PD 2024 | Challenges in fluid biomarker development in Alzheimer’s disease research

Bjørn-Eivind Kirsebom, PhD, University Hospital of North Norway, Tromsø, Norway, comments on the need for fluid biomarkers that can predict progression in Alzheimer’s disease (AD). Cerebrospinal fluid (CSF) markers can reliably detect amyloid plaques, however some cases with plaques progress slowly or never develop to mild cognitive impairment (MCI) or dementia. Numerous contenders are under investigation, including synaptic markers. Another limitation comes from the lack of specificity of current markers. GFAP and p-tau217, for example, rise in various neurodegenerative diseases, not just AD. This interview took place at the AP/PD 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.